Neuromyelitis Optica Spectrum Disorder Market Size and Share, Epidemiology and Market Research Forecast 2032 | Companies – Bio-Thera Solutions, RemeGen, Harbour BioMed
DelveInsight launched a new report on Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Insights, Epidemiology and Market Forecast 2032.
Neuromyelitis Optica spectrum disorder (NMOSD), also known as Devic disease, is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis).
DelveInsight’s “Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Report 2032“ delivers an in-depth understanding of the Neuromyelitis Optica Spectrum Disorder (NMOSD), historical and forecasted epidemiology as well as the Neuromyelitis Optica Spectrum Disorder (NMOSD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Classically, it was felt to be a monophasic illness, consisting of episodes of inflammation of one or both optic nerves and the spinal cord over a short period (days or weeks) but, after the initial episode, no recurrence.
It is now recognized that most patients satisfying current criteria for NMOSD experience repeated attacks separated by periods of remission. The interval between attacks may be weeks, months, or years. In its early stages, NMOSD may be confused with multiple sclerosis (MS).
Request for free sample pages of the report: https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market
NMOSD can affect children as young as 3 years and adults as old as 90 years. The onset of NMOSD varies from childhood to adulthood, and the average age of onset is about 40.
NMOSD Treatment Options:
- Preventive treatment (immunosuppressive medications, mycophenolate mofetil, Azathioprine and rituximab)
- Approved therapy (Soliris (eculizumab), Uplinza (inebilizumab-cdon), Enspryng (satralizumab))
- Acute treatment (methylprednisolone, corticosteroids)
- Symptomatic treatment (anti-epileptic medications, anti-spasmodics)
NMOSD Key pharma players involved:
- Bio-Thera Solutions
- RemeGen
- Harbour BioMed
The NMOSD market size shall grow during the forecast period owing to the launch of upcoming therapies and is expected to increase at a CAGR of XX during the study period.
Click here and download sample pages of the NMOSD Market Report 2032
Table of contents:
Table of contents:
1 Key Insight
2 Executive Summary of Neuromyelitis Optica Spectrum Disorder (NMOSD) market
3 Neuromyelitis Optica Spectrum Disorder (NMOSD) market, Market Overview at a Glance
4 Disease Background and Overview: Neuromyelitis Optica Spectrum Disorder (NMOSD) market,
5 Case Reports
6 Neuromyelitis Optica Spectrum Disorder (NMOSD) market, Epidemiology and Patient Population
7 United States Epidemiology
8 EU5 Epidemiology
9 Japan Epidemiology
10 Current Neuromyelitis Optica Spectrum Disorder (NMOSD) market, Treatment and Medical Practices
11 Unmet needs
12 Neuromyelitis Optica Spectrum Disorder (NMOSD) market, Marketed Drugs
13 Neuromyelitis Optica Spectrum Disorder (NMOSD) market, Emerging Drugs
14 Neuromyelitis Optica Spectrum Disorder (NMOSD) market, 7MM Market Analysis
15 United States
16 EU-5 countries: Market Outlook
17 Japan Market Outlook
18 Neuromyelitis Optica Spectrum Disorder (NMOSD) market, Market Drivers
19 Neuromyelitis Optica Spectrum Disorder (NMOSD) market, Market Barriers
20 SWOT Analysis
21 Reimbursement and market access
22 Appendix
23 DelveInsight Capabilities
24 Disclaimer
25 About DelveInsight
Download report: https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/